Change over period: —
NSE · GKSL
GKSL
-22.1% from the 52-week high · +52.7% above the low
Gujarat Kidney & Super Speciality Ltd operates in the healthcare sector, specializing in nephrology and super-specialty medical services. The company manages healthcare facilities offering dialysis, kidney care, and related clinical services. Its operations focus on patient care, specialized medical infrastructure, and qualified professionals. The business model is service-oriented, generating revenue through treatments, procedures, and hospital services. Demand is driven by chronic care requirements and healthcare access needs.
The short version. GKSL reported revenue of ₹38 crore for Sep 2026, up 192.3% from a year earlier. Net profit was ₹6 crore (up 100.0% year on year). Return on equity was 6.1% in Mar 2026. Promoter holding was 71.45% in Sep 2026, up 0.00 points over 5 quarters.
1 · The price
How has the stock traded?
GKSL trades 22.1% below its 52-week high and 52.7% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹38 cr.
Sep 2026 net profit of ₹6 cr.
5.3 pts lower than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Revenue | 38 | 34 | 31 | 23 | 13 |
| Net profit | 6 | 5 | 5 | 3 | 3 |
| Net margin % | 15.3 | 15.1 | 16.5 | 12.7 | 20.6 |
| EPS (₹) | 0.74 | 0.66 | 0.64 | 0.37 | 0.34 |
Annual
| FY2026 | |
|---|---|
| Revenue | 82 |
| Net profit | 15 |
| Net margin % | 18.9 |
| EPS (₹) | 1.97 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 6.1% in Mar 2026; debt to equity is 0.06.
Profitability · 1 years
Returns and margins
| Mar 2026 | |
|---|---|
| Return on equity % | 6.1 |
| Return on capital % | 8.6 |
| EBITDA margin % | 33.6 |
| Net margin % | 18.7 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Unchanged over 5 quarters.
Down 6.56 pts over 5 quarters.
Down 7.58 pts over 5 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|
| Promoter | 71.45 | 71.45 | 71.45 | 71.45 | 71.45 | 0.0 |
| FII | 13.09 | 10.47 | 4.88 | 4.88 | 6.53 | -6.56 |
| DII | 7.84 | 1.67 | 0.56 | 0.56 | 0.26 | -7.58 |
| Public | 7.62 | 16.4 | 23.1 | 23.1 | 21.77 | +14.15 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Motilal Oswal BSE Healthcare ETF0.02% of NAV
- Bandhan BSE Healthcare Index Fund0.02% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for GKSL are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about GKSL
What is the GKSL share price?
GKSL (GKSL) last closed at ₹150.50, down 0.8% on the day. Its 52-week range is ₹99.36 to ₹194.69.
What is the market cap of GKSL?
GKSL has a market capitalisation of about ₹1,199 crore. Its price-to-earnings ratio is 26.8.
How are GKSL's latest results?
GKSL reported revenue of ₹38 crore for Sep 2026, up 192.3% from a year earlier. Net profit was ₹6 crore (up 100.0% year on year). Return on equity was 6.1% in Mar 2026. Promoter holding was 71.45% in Sep 2026, up 0.00 points over 5 quarters.
Who owns GKSL?
As of Sep 2026, shareholding was: Promoter 71.45%, FII 6.53%, DII 0.26%, Public 21.77%.
How many mutual funds hold GKSL?
2 mutual fund schemes held GKSL in October 2026. That compares with 2 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.